Human Genome Sciences
Executive Summary
Pulmozyme (DNase) cystic fibrosis treatment marketer Genentech receives exclusive option to license the heart/lung selective DNase (HL-DNase) gene from Rockville, Md.-based gene sequencing company. The agreement, announced April 20, "represents the first example of HGS initiating commercial development of a technology" that has been released by its development partner SmithKline Beecham. SB will share "any proceeds" from the Genentech agreement